Luminex offers a broad menu of Research Use Only (RUO)1 products for pharmacogenetics based on xMAP® Technology.
Pharmacogenetics studies the influence of genetic variation on drug response. Knowledge of gene variants causing differences in drug response among individuals is considered to have the potential to allow “personalized” therapy. There are several genes responsible for differences in drug metabolism. Among the most common are the cytochrome P450 (CYP) genes. Cytochrome P450s are a family of enzymes that catalyze the conversion of lipophilic substances into hydrophilic molecules that can then be excreted by the kidneys into the urine. They represent a major part of the body’s powerful detoxification systems. The five main cytochrome P450 enzymes, CYP2D6, CYP2C19, CYP2C9, and the CYP3A4 and CYP3A5 system metabolize much of the endogenous substrates through various reactions.2
xTAG® Technology allows the possibility of assessing an individual’s specific genetic variation in select CYP genes, thus enabling greater understanding of the relation between genetic variation and response to drugs.
|Pharmacogenetic Assay||Part Number||Kit Size|
|xTAG CYP2D6 v3 Kit||X030B0411||48 tests|
|xTAG CYP2C19 v3 Kit||X046B0429||48 tests|